RGEN
NASDAQRepligen Corporation
News · 26 weeks53-78%
2026-03-012026-08-23
Mix1390d
- SEC Filings5(38%)
- Insider3(23%)
- Earnings3(23%)
- Analyst2(15%)
Latest news
25 items- SECSEC Form S-4 filed by Repligen CorporationS-4 - REPLIGEN CORP (0000730272) (Filer)
- INSIDERChief Executive Officer Loeillot Olivier exercised 5,426 shares at a strike of $141.79 and sold $976,680 worth of shares (5,426 units at $180.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- SECSEC Form 10-Q filed by Repligen Corporation10-Q - REPLIGEN CORP (0000730272) (Filer)
- SECRepligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REPLIGEN CORP (0000730272) (Filer)
- PRRepligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial GuidanceSecond quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organicGAAP operating income increased 1% year-over-year while adjusted operating income increased 55%Raising both FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09 WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2026, covering the three-month period ended June 30, 2026. The Company is also providing updated financial guidance for the full year 2026. Olivier Loeillot, President and Chief Executive
- SECSEC Form 425 filed by Repligen Corporation425 - REPLIGEN CORP (0000730272) (Subject)
- SECRepligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - REPLIGEN CORP (0000730272) (Filer)
- PRRepligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation MediaFast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and Repligen common stock at a value of $31.00 per share, representing a total enterprise value of approximately $1.5 billion Compelling financially, the transaction is expected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least 5 cents in year one and at least 25 cents in year two Repligen reports preliminary second quarter reported revenue growth of approximately 12% or 13% organic; BioLife reports preli
- INSIDERCFO Garland Jason K sold $79,500 worth of shares (530 units at $150.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 18,829 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- PRRepligen to Report Second Quarter 2026 Financial ResultsWALTHAM, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its second quarter 2026 financial results on Tuesday, July 28, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended June 30, 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 768981187. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The
- ANALYSTRepligen upgraded by The Benchmark Company with a new price targetThe Benchmark Company upgraded Repligen from Hold to Buy and set a new price target of $185.00
- INSIDERCFO Garland Jason K sold $106,285 worth of shares (733 units at $145.00) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 19,359 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- ANALYSTWolfe Research resumed coverage on Repligen with a new price targetWolfe Research resumed coverage of Repligen with a rating of Outperform and set a new price target of $145.00
- PRRepligen Corporation to Present at William Blair 46th Annual Growth Stock ConferenceWALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a global life sciences company that de
- PRRepligen Announces Publication of the Company's 2025 Corporate Sustainability ReportWALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate Sustainability Report and related reporting framework disclosures. Themed "Driving Sustainable Growth Together", this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success. Also included in the 2025 Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and three
- INSIDERDirector Pax Margaret was granted 995 shares, increasing direct ownership by 49% to 3,011 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Eglinton Manner Carrie was granted 995 shares, increasing direct ownership by 22% to 5,461 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Mhatre Rohin was granted 995 shares, increasing direct ownership by 25% to 5,014 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Madaus Martin D was granted 995 shares, increasing direct ownership by 18% to 6,581 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Konstantinov Konstantin was granted 995 shares, increasing direct ownership by 34% to 3,889 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Dawes Karen A was granted 995 shares, increasing direct ownership by 1% to 92,816 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Barthelemy Nicolas was granted 995 shares, increasing direct ownership by 22% to 5,436 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Muir Glenn P was granted 995 shares, increasing direct ownership by 3% to 40,051 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- ANALYSTRBC Capital Mkts resumed coverage on Repligen with a new price targetRBC Capital Mkts resumed coverage of Repligen with a rating of Outperform and set a new price target of $160.00
- SECRepligen Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - REPLIGEN CORP (0000730272) (Filer)
RGEN FAQ
7 questionsWhat does Repligen Corporation do?
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance...Where does RGEN stock trade?
Repligen Corporation (RGEN) is listed on NASDAQ.What sector and industry is RGEN in?
Repligen Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Repligen Corporation go public?
Repligen Corporation (RGEN) completed its IPO in 1986.What are analysts saying about RGEN?
Repligen Corporation has had 8 recent analyst actions on file. The most recent action was from The Benchmark Company: Buy on 2026-07-07.What companies are similar to RGEN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare RGEN side-by-side with any of them on Quantisnow.How can I track RGEN on Quantisnow?
Quantisnow aggregates Repligen Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGEN to receive live email and push alerts on every new disclosure.